Skip to content

Study · PubMed tag: Meta-Analysis, Systematic Review · 2022

Retracted

Effects of Misoprostol on Induction of Labour in Patients with Hypertensive Disorders of Pregnancy: A Meta-Analysis.

Wang L, Liu S, Song G, Gao M, Liu T

Journal of healthcare engineering8 Apr 2022Cited by 1 (Europe PMC)

PMID35432818 (opens in a new tab)PMCIDPMC9012620 (opens in a new tab)DOI10.1155/2022/8448690 (opens in a new tab)PepBankPUB-35432818
Download PDFPubMedAsk about this study

Summary

ObjectiveHypertensive disorders of pregnancy (HDP) can cause serious prenatal and postnatal complications and is a threat to maternal and fetal health. To offer guidance for clinical decisions, we systematically reviewed the effects of misoprostol on induction of labour in HDP patients.MethodsPubMed, Web of Science, Embase, CNKI, and Wanfang databases were searched for relevant literature from 2010 to 2020. Subsequently, a meta-analysis was performed to compare the effective rate of induction of labour and reducing postpartum hemorrhage (PPH) between the intervention group (n = 544, misoprostol) and the control group (n = 543, oxytocin).ResultsA total of 10 studies with 1087 patients were included. The 10 studies compared the effective rate of induction of labour between the two groups and confirmed that the effective rate in the intervention group was significantly higher than that in the control group (OR = 4.37; 95% CI: 2.73, 7.00). Seven studies compared PPH between the groups and showed that it was significantly reduced in the intervention group compared to the control group (SMD = -1.32; 95% CI: -2.05, -0.59; P < 0.0001).ConclusionMisoprostol has a high effective rate of induction of labour in HDP patients and is an effective uterotonic agent in reducing PPH. This meta-analysis provides clinicians with meaningful information to help them make evidence-based decisions.
CC BYText from Europe PMC. No result points at this text yet.

Results from this study

This kind of study is outside PepBank.

Read at the source

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Versions 2 to 10Current

    27 Oct 2026, 16:37 UTC

    The same notice was added 9 times, first on 9 Oct 2026, 03:15 UTC. The status did not change between them.

    Status changed: status, notices · status retracted · status notice from Retraction Watch (Crossref)

  2. Version 1

    9 Oct 2026, 02:49 UTC

    First added · status retracted · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.